Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

Incyte received a Rare Pediatric Disease Priority Review Voucher tied to zilurgisertib’s FOP approval, while Mirum plans U.S.

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...

Pharmaceutical Executive spoke with Michael Abrams, managing partner at global healthcare consultancy Numerof & Associates ...

Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient ...

FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and ...

FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...

The FDA's movement to encourage real-world data use through downstream acceptance is, in effect, a call to action for ...

As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to ...

Chief executives from nine of Europe's largest drugmakers are calling on the European Union (EU) and its member states to ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...